The JUPITER Trial: Results, Controversies, and Implications for Prevention
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systemic inflammation as measured by high sensitivity C-reactive protein (hs-CRP), is an example of a well-established patient vulnerability factor that has predictive value in terms of cardiovascular events14.”
From Rac2 Modulates Atherosclerotic Calcification by Regulating Macrophage Interleukin-1β Production (2017) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationRidker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“JUPITER was a formal hypothesis testing trial based on prior observations that (1) inflammation plays a crucial role in atherogenesis2; (2) that the inflammatory biomarker hsCRP independently predicts vascular events and improves global classification of risk regardless of LDLC level3–6; (3) that statin therapy reduce…”
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationRidker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationRidker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citationRidker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Self-citationStatin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citation
Research works printed but not linked: 13
- 10.1038/nri1882 · DOI · Paper page
- 10.1161/circ.100.3.230 · doi:10.1161/circ.100.3.230
- 10.1001/jama.286.1.64 · DOI · Paper page
- 10.1161/circ.98.9.839 · doi:10.1161/circ.98.9.839
- 10.1161/circulationaha.106.628909 · DOI · Paper page
- Glynn RJ Danielson E Fohnseca FAH. A randomized trial of rosuvastatin to prevent venous thromboembolism [published online ahead of print March 29 2009]. N Eng J Med. (10.1056/NEJMoa0900241). · DOI · Paper page
- 10.1161/01.atv.0000151647.14923.ec · DOI · Paper page
- 10.7326/0003-4819-146-12-200706190-00010 · DOI
- 10.1001/jama.282.20.1899 · DOI
- 10.1161/circ.103.3.357 · doi:10.1161/circ.103.3.357
- 10.1373/clinchem.2008.120642 · DOI · Paper page
- 10.1373/clinchem.2008.115899 · DOI · Paper page
- 10.1016/j.jacc.2005.02.080 · DOI · Paper page
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Old and new generation lipid mediators in acute inflammation and resolution
Stables, M. J., & Gilroy, D. W. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.07.005 · Cited by 334
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
“84).(61) Patients who achieved LDL-C ,70 mg/dL and CRP ,2.”
BackgroundAllaire, J., Couture, P., Leclerc, M., Charest, A., Marin, J., Lépine, M.-C., Talbot, D., Tchernof, A., & Lamarche, B. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.131896 · Cited by 252
“2 mg/L) was highly effective in reducing risk of vascular events, myocardial infarction, and stroke (29).”
Background
Metadata
- Authors
- Ridker, P. M.
- Affiliations
- From the Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2009-05
- Volume
- 2
- Issue
- 3
- Pages
- 279-285
- ISSN
- 1941-7713
- 1941-7705
- Cited by
- 114
- References
- 11
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The JUPITER Trial: Results, Controversies, and Implications for Prevention. https://app.cochat.ai/papers/10.1161/circoutcomes.109.868299
- The paper
- Ridker, P. M. (2009). The JUPITER Trial: Results, Controversies, and Implications for Prevention. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.109.868299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.